Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Trimetrexate Glucuronate Inj Articles

US Biosciences halts lodenosine HIV trial after death of patient

15 October 1999

USB plans 2000 filing for NeuTrexin in CRC

26 May 1999

US Drug Majors See 2nd-Half Double-Digit Growth

29 July 1996

USB, Alza Extend Product Collaboration

3 June 1996

US Bioscience Signs Euro Marketing Deal

17 July 1995

Eli Lilly Canada; Hexalen and Ethyol

8 May 1995

New Chemical Entities Round-Up For 1994

6 February 1995

First Approval For Ethyol, But FDA Panel Says No

19 December 1994

1st Cytoprotectant Set For EU Approval

3 October 1994

ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES

31 January 1994

FDA YEAR-END APPROVALS FOR 1993

10 January 1994

US BIOSCIENCE'S AIDS-RELATED DRUG APPROVED

10 January 1994

NEUTREXIN TREATMENT IND

21 June 1993

US BIO TO FILE NEW NDA FOR ETHYOL?

29 March 1993

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS